XmAb2513

· Xencor, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for XmAb2513, covering 2014-04-21 to 2014-04-21. Get the full timeline:

Most recent: Clinical Trial Update: Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma [Phase 1]